20Med Therapeutics appoints Allard Kaptein to Supervisory Board

Friday, November 1, 2019

20Med Therapeutics BV, a biotechnology company developing innovative nanoparticles for delivery of RNA therapeutics today announced the appointment of Dutch biotech veteran and serial entrepreneur Allard Kaptein to its Supervisory Board.

“We are delighted to welcome Allard to our supervisory board” commented Michiel Lodder, CEO of 20Med Therapeutics. “at this stage of development of 20Med his expert advice and experience in drug development are a valuable addition to the company”.

Dr. Allard Kaptein is Managing Director of Genase Therapeutics. Prior to that, he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma, which resulted in the now FDA approved drug acalabrutinib in 2017. Dr. Kaptein is an expert in Drug Discovery and in translating science from bench to clinic and from the clinic back to identification of new targets and understanding of mechanism of action. In total, he has over 25 years’ experience in the pharmaceutical industry in Oncology, Autoimmune Diseases, and Cardiovascular Diseases. He held various positions of increasing responsibilities at Glaxo(Wellcome), Organon, Schering Plough, and MSD.

Dr. Kaptein holds a PhD in Biopharmaceutical Sciences from the University Leiden, with studies performed at the Gaubius Institute TNO in Leiden, The Netherlands.

“20Med Therapeutics has developed a unique proprietary technology that may be used broadly for different therapeutic approaches,” said Dr. Kaptein. “It is a privilege to contribute to 20Med Therapeutics' future steps in translating the scientific potential present within the company to therapeutic opportunities for patients in need of new treatment options”.

About 20Med Therapeutics

20Med Therapeutics is a Dutch biotechnology company developing innovative therapeutics based on its proprietary delivery technology. 20Med’s non-viral delivery platform is based on bioresponsive polymers specifically designed for the efficient intracellular delivery of oligonucleotides. 
For more information, visit www.20medtx.com

Find out more about drug development at Leiden Bio Science Park.

R&D